Feed / WST

West Pharmaceutical Services, I

WST

Healthcare · 341.01 +0.5% today

Jodie read · what matters now

Revenue increased 21.0% versus the comparable filing period.

The story is only the start. Jodie keeps watching the filing evidence, the companies connected to WST, and whether its market group begins moving.

Latest storyNo Struct brief yetJodie is monitoring new filings.
Disclosed connections1 verified linkBuilt from company filings
Organic co-movement groupInjectable Drug Delivery · LeaderLast observed group; it is between live snapshots · See active groups →

Latest filing assessment · baseline

Fundamentals strengthened in the latest filing

10-Q filed 2026-04-23 against the comparable filing from 2025-04-24.

constructive
OperationsconstructiveEvidence score +4
liquidityneutralEvidence score 0
valuationmixed

What improved

  • Revenue increased 21.0% versus the comparable filing period.
  • Operating margin improved 5.6 percentage points.
  • Net income increased 54.6% versus the comparable filing period.

What weakened

No thresholded deterioration was identified.

Filing receipts

West Vantage gross profit margin decreased by 0.6 margin points for the three months ended March 31, 2026, as compared to the same period in 2025, due primarily to increased production costs, partially offset by sales price increases.

Proprietary Products - Proprietary Products operating profit increased by $58.6 million, or 44.9%, for the three months ended March 31, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impa ct of $12.4 million , due to the factors described above, most no tably increased customer demand, primarily of high value components, and sales price increases.

West Vantage - West Vantage operating profit increased by $2.1 million , or 15.6%, for the three months ended March 31, 2026, as compared to the same period in 2025, including a favorable foreign currency translation impact of $1.0 million , due to the factors described abov e, most notably sales price increases and foreign exchange gains, partially offset by increased production costs.

Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.

Who this business touches

The relationships behind WST

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

Filing peers

Companies whose filings use similar operating language.

You can see the shape of the network here. Pro opens the original filing receipts, and alerts when connected names begin moving. See Pro →

What is moving around it

Live connections

WST is currently a Leader in the organic co-movement group Injectable Drug Delivery. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.

This group is retained as the last observed read for WST; it is not active in the latest market snapshot.

Theme membership history

No durable theme membership has been observed for this name yet.